NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
Loading market information…
NASDAQ · ABUS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Arbutus Biopharma Corp’s quoted price sits in the lower half of its reported 52-week range, 21.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Arbutus Biopharma Corp’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Arbutus Biopharma Corp’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$0.13-44.44% vs estimate | $1.76M-21.32% vs estimate |
|---|
| Q4 2024 | Mar 27, 2025 | -$0.07+12.5% vs estimate | $1.57M-30.26% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.100.0% vs estimate | $1.34M-15.25% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
$60.49+$0.28 (+0.47%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.65% below the high.
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$11.15-$0.40 (-3.46%)
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
$8.83+$0.03 (+0.34%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
